Drug Profile
LLF 580
Alternative Names: LLF580Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Novartis Pharmaceuticals
- Class Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for phase-I development in Obesity in USA (SC, Injection)
- 25 Jul 2019 Novartis Pharmaceuticals completes a phase I trial in Obesity in USA (SC) (NCT03466203)
- 26 Feb 2018 Phase-I clinical trials in Obesity in USA (SC) (NCT03466203)